Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era

For limited disease, response-adaptive therapy demonstrated comparable outcomes with RT alone. Rituximab monotherapy resulted in inferior outcomes for limited disease and a high relapse rate for advanced disease.